Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA7 | P43166 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27594635 | 0.88 | NOTUM (0.54) | NOTUMCA1CA2CA12CA7 | |
| SCHEMBL29172065 | 0.88 | NOTUM (0.54) | NOTUMCA1CA2CA12CA7 | |
| SCHEMBL31733373 | 0.87 | NOTUM (0.53) | NOTUMCA1CA2CA12CA7 | |
| SCHEMBL15300311 | 0.86 | NOTUM (0.55) | NOTUMCA1CA2CA12CA7 | |
| SCHEMBL25949222 | 0.85 | NOTUM (0.58) | NOTUMCA1CA2CA12CA7 | |
| SCHEMBL13220716 | 0.84 | CA1 (0.53) | CA1CA2CA12CA7CA9 | |
| SCHEMBL2627855 | 0.81 | CA1 (0.50) | NOTUMCA1CA2CA12CA7 | |
| SCHEMBL11438477 | 0.81 | CA1 (0.65) | CA1CA2CA12CA7CA9 | |
| SCHEMBL8080620 | 0.80 | ACE2 (0.56) | CA1CA2CA12CA7CA9 | |
| SCHEMBL12151586 | 0.80 | NOTUM (0.64) | NOTUMCA1CA2CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210094927-A1 | ISOTOPICALLY-STABILIZED TETRONIMIDE COMPOUNDS | MIDWESTERN UNIVERSITY | 2021-04-01 | — | — | US | disclosed |
| US-10961211-B2 | Isotopically-stabilized tetronimide compounds | MIDWESTERN UNIVERSITY (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200262804-A1 | Isotopically-Stabilized Tetronimide Compounds | MIDWESTERN UNIVERSITY | 2020-08-20 | — | — | US | disclosed |
| US-10342795-B2 | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives as ROS1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2019-07-09 | — | — | US | disclosed |
| US-10280170-B2 | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as Ros1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-07 | — | — | US | disclosed |
| EP-3129376-B1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-A][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-12-26 | — | — | EP | disclosed |
| EP-3126366-B1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND 2,3-DIHYDRO-1H-IMIDAZO[1,2-B]PYRAZOLE DERIVATIVES AS ROS1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-06 | — | — | EP | disclosed |
| US-20170173014-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND 2,3-DIHYDRO-1H-IMIDAZO[1,2-b]PYRAZOLE DERIVATIVES AS ROS1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-22 | — | — | US | disclosed |
| US-20170174690-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-22 | — | — | US | disclosed |
| EP-3129376-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-A][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2017-02-15 | — | — | EP | disclosed |
| EP-3126366-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND 2,3-DIHYDRO-1H-IMIDAZO[1,2-B]PYRAZOLE DERIVATIVES AS ROS1 INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2017-02-08 | — | — | EP | disclosed |
| WO-2015144799-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-01 | — | — | WO | disclosed |
| WO-2015144801-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND 2,3-DIHYDRO-1H-IMIDAZO[1,2-b]PYRAZOLE DERIVATIVES AS ROS1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-01 | — | — | WO | disclosed |
| US-7105536-B2 | Compounds | SMITHKLINE BEECHAM PLC (GB) | 2006-09-12 | — | — | US | disclosed |
| US-6770657-B2 | ARYL OR HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINE DERIVATES POSSESS ANTI-CONVULSANT ACTIVITY AND ARE THEREFORE BELIEVED TO BE USEFUL IN THE TREATMENT AND/OR PREVENTION OF MANY DISEASES | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-08-03 | — | — | US | disclosed |
| US-20040142964-A1 | Novel compounds | SMITHKLINE BEECHAM P.L.C. | 2004-07-22 | — | — | US | disclosed |
| EP-1367055-A1 | Isoquinolinyl carboxamides and their use as anticonvulsants | SMITHKLINE BEECHAM PLC (GB) | 2003-12-03 | — | — | EP | disclosed |
| US-20030036551-A1 | Novel compounds | SMITHKLINE BEECHAM P.L.C. | 2003-02-20 | — | — | US | disclosed |
| US-6492388-B1 | SUCH AS N-(5-CHLORO-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL)-4-ETHOXYBENZAMIDE | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036551-A1 | Novel compounds | SCN1B, CNR1, SCN1A | NOTUM 1544/4885CA1 625/4885CA2 678/4885 |
| US-10961211-B2 | Isotopically-stabilized tetronimide compounds | ASPH, BACE1, DNPEP | NOTUM 898/4885CA1 294/4885CA2 2174/4885 |
| US-20200262804-A1 | Isotopically-Stabilized Tetronimide Compounds | ASPH, BACE1, DNPEP | NOTUM 898/4885CA1 294/4885CA2 2174/4885 |
| US-20210094927-A1 | ISOTOPICALLY-STABILIZED TETRONIMIDE COMPOUNDS | ASPH, BACE1, DNPEP | NOTUM 898/4885CA1 294/4885CA2 2174/4885 |
| US-10280170-B2 | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as Ros1 inhibitors | ROS1, NOX1, NOX5 | NOTUM 2329/4885CA1 3207/4885CA2 2712/4885 |
| US-20040142964-A1 | Novel compounds | GRIN2C, GRIN2A, NLN | NOTUM 3391/4885CA1 1334/4885CA2 2967/4885 |
| US-10342795-B2 | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives as ROS1 inhibitors | ROS1, NOX1, NOX4 | NOTUM 2594/4885CA1 4278/4885CA2 2568/4885 |
| US-20170174690-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS | ROS1, NOX1, NOX5 | NOTUM 2329/4885CA1 3207/4885CA2 2712/4885 |
| US-20170173014-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND 2,3-DIHYDRO-1H-IMIDAZO[1,2-b]PYRAZOLE DERIVATIVES AS ROS1 INHIBITORS | ROS1, NOX1, NOX4 | NOTUM 3347/4885CA1 4428/4885CA2 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.